- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02574325
A Study to Assess ARI-3037MO on Hepatic Fat Metabolism in Patients With Dysglycemia and Evidence of Hepatic Steatosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This randomized,double-blind, placebo-controlled study will enroll 36 men and women with a diagnosis of NAFLD orNASH. The study will be conducted over a period of approximately 28 wks and will include:a Screening Phase (Days -14to -1); a 24-week long Treatment Phase, during which patients will be randomly assigned to receive ARI-3037MO or placebo; an End-of-study Visit (ESV) scheduled 2 wks after the end of the Treatment Phase The Screening Phase will include 2 visits. Visit 1:There will be an initial assessment of a patient's eligibility for participation in the study. A complete medical history will be obtained and prospective study patients will undergo physical examinations and laboratory evaluations. For patients who have had a liver biopsy in the 6months prior to Visit 1, the histology findings, i.e., NAS, steatosis score and fibrosis score will be recorded. Visit 2:Approximately 1 week after Visit 1, and after the results of clinical laboratory screening test results have been reviewed by the Principal Investigator (PI), patients will be contacted to advise them of their eligibility to continue in the study. Eligible patients will undergo liver magnetic resonance imaging (MRI) to assess intrahepatic fat content. Treatment Phase Patients with MRI results showing intrahepatic fat content of ≥10% will be entered into the Treatment Phase of the study. The Treatment Phase will include 4 outpatient visits over a period of 24 weeks. Visit 3:Patients will be randomly assigned to receive ARI-3037MO or placebo on Day 1 of a 24-week long outpatient treatment period. Baseline assessments, including FibroTest®, FibroScan® and clinical laboratory tests, will be performed, and patients will take study drug twice daily. Visits 4, 5 and 6: During the Treatment Phase, patients will visit the study clinic at 4, 12 and 24 weeks (± 4 days) after Day 1 for evaluations and examinations and to collect study drug. Twenty-four weeks after the start of dosing, at the end of the Treatment Phase, patients will undergo a follow-up MRI and FibroScan† to assess change from baseline in intrahepatic fat content and liver fibrosis, respectively.
†If FibroScan equipment is available at the study site End-of-Study Visit Visit 7:An ESV will occur 2 weeks (± 4 days) after the end of the Treatment Phase.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Missouri
-
St Louis, Missouri, United States, 63104
- Gastroenterology & Hepatology CRU, St Louis University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female patients ≥ 18 years of age at study entry
- Female patients must be of nonchildbearing potential
- Have a stable diet and agree to maintain this diet throughout the study
- Have not gained or lost ≥ 10 lbs (4.5 kg) of body weight within 6months prior to Screening Visit 1
- Have a body mass index (BMI) between 28 and 45 kg.m-2, inclusive
- Have elevated alanine aminotransferase (ALT) levels. For men: 50 IU/L to 250 IU/L, inclusive. For women: 40 IU/L to 240 IU/L, inclusive.
- Have HbA1c of < 9.5
- Have a intrahepatic fat content of ≥ 10% confirmed by liver MRI
- If taking antidiabetic therapies (excluding thiazolidines as per exclusion Criterion No. 13), i.e., metformin, sulfonylureas, dipeptidyl peptidase-4 inhibitors, insulin; must be on a stable dose for at least 3months prior to Screening Visit 1. Similarly, if taking lipid lowering therapies; must be on a stable dose for at least 3 months prior to Screening Visit 1.
- Understands the study requirements and the treatment procedures, is willing to comply with all protocol-required evaluations and provides written informed consent before any study specific tests or procedures are performed
Exclusion Criteria:
- A history of hepatic disease such as chronic hepatitis C virus or concurrent active hepatitis B virus (i.e., serum positive for hepatitis B surface antigen)
- Autoimmune hepatitis
- Primary biliary cirrhosis
- Sclerosing cholangitis
- Hereditary hemochromatosis
- History of chronic / repeat blood transfusion (i.e., ≥ 20 units of blood)
- Alpha-1 anti-trypsin deficiency
- Wilson's disease
- Thyroid disease
- Bariatric surgery within 5 years prior to Screening Visit 1
- Hepatic disease due to substance abuse
- Have any concurrent disease or condition not listed above that, in the opinion of the PI, would make the patient unsuitable for participation in the study
- Currently taking thiazolidines (glitazone therapy, i.e., Rosiglitazone, Pioglitazone)
- Liver biopsy in the past 90 days with negative results for cirrhosis and steatosis
- No evidence of hepatic decompensation or elevated serum bilirubin > 1.5 times the upper limit of normal
- Estimated glomerular filtration rate < 60 mL/min according to the Modification of Diet in Renal Disease equation
- Known substance abuse
- Current smoker or a history of smoking (> 10 cigarettes, > 3 cigars or > 3 pipes/day)
- Current consumption of > 3 units of alcohol per day (> 21 units per week) for men and > 2 units of alcohol per day (> 14 units per week) for women
- Currently participating in another clinical study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Control
|
Experimental: ARI-3037MO
|
Treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy as measured by change in intra hepatic fat content
Time Frame: 24 wks
|
Change in intra hepatic fat content by MRI
|
24 wks
|
Efficacy as measured by change in plasma ALT levels
Time Frame: 24 wks
|
Change in plasma ALT levels from baseline
|
24 wks
|
Efficacy as measured by change in plasma TG levels
Time Frame: 24 wks
|
Change in plasma TG levels from baseline
|
24 wks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety as measured by the occurrence of flushing (number of episodes) and itching (number of episodes)
Time Frame: 24 wks
|
Occurrence of cutaneous symptoms
|
24 wks
|
Safety as measured by effect of ARI-3037MO on on glycemic control
Time Frame: 24 wks
|
Change in HbA1c levels from baseline
|
24 wks
|
Safety as measured by effect of ARI-3037MO on serum bilirubin, alkaline phosphatase, Prothrombin time and plasma albumin levels
Time Frame: 24 wks
|
Change of liver function tests from baseline
|
24 wks
|
Safety as measured by effect of ARI-3037MO on gastrointestinal systems; episodes of nausea, vomiting and diarrhea
Time Frame: 24 wks
|
occurrence of GI symptoms
|
24 wks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ARI-3037MO-006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nonalcoholic Steatohepatitis
-
Duke UniversityCompletedLiver Diseases | Nonalcoholic Steatohepatitis (NASH) | Nonalcoholic Steatohepatitis | Nonalcoholic Fatty LiverUnited States
-
Gilead SciencesCompletedNonalcoholic Steatohepatitis (NASH) | Nonalcoholic Fatty Liver Disease (NAFLD)United States, New Zealand
-
National Institute of Diabetes and Digestive and...CompletedNonalcoholic Steatohepatitis (NASH) | Nonalcoholic Fatty Liver Disease (NAFLD)United States
-
Polaris GroupRecruiting
-
Corcept TherapeuticsRecruitingNonalcoholic Steatohepatitis (NASH)United States
-
PerspectumRecruitingNASH - Nonalcoholic SteatohepatitisUnited States
-
Metacrine, Inc.Completed
-
Cascade Pharmaceuticals, IncLaboratory Corporation of AmericaCompletedNonalcoholic Steatohepatitis (NASH)United States
-
Poxel SACompletedNASH - Nonalcoholic SteatohepatitisUnited States
-
RWTH Aachen UniversityCompletedNASH - Nonalcoholic SteatohepatitisSweden, Austria, Germany
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States